Genesis Therapeutics

Genesis Therapeutics (now Genesis Molecular AI) uses deep learning to discover small molecule drugs against challenging and undruggable protein targets. The company's GEMS platform combines AI with an integrated wet lab to navigate vast chemical space with precision. Backed by a16z, Eli Lilly, Fidelity, and BlackRock, Genesis has raised over $300M and secured a strategic collaboration with Incyte.

$304M+

Total raised

GEMS (Genesis Exploration of Molecular Space) platform integrates deep learning with an in-house wet lab for rapid design-make-test cycles. Specializes in data-poor and undruggable targets where traditional computational approaches fail.